Slide 1: Invivyd CANOPY Data Update
Exhibit 99.2 INVIVYD CANOPY DATA UPDATE August 27, 2024 © 2024 Invivyd, Inc. Invivyd , Pemgarda , and the Ribbon logos are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners.
Slide 2: Cautionary Note Regarding Forward-Looking Statements
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words
Slide 3: COVID-19 Prophylaxis via Monoclonal Antibody: A Step Forward
COVID-19 PROPHYLAXIS VIA MONOCLONAL ANTIBODY: A STEP FORWARD • CANOPY exploratory clinical efficacy data demonstrated a substantial change - 84% Relative Risk Reduction (RRR) – in experiencing symptomatic COVID-19 disease with pemivibart 1 prophylaxis versus placebo (TM) • PEMGARDA (pemivibart) Fact
Slide 4: CANOPY COVID-19 PrEP Results Are the First Reported in a Contemporary, Endemic Virus Population
CANOPY COVID-19 PREP RESULTS ARE THE FIRST REPORTED IN A CONTEMPORARY, “ENDEMIC VIRUS” POPULATION Study Molecule(s) Protocol Participation Criteria Include: Tests negative for prior SARS-CoV-2 infection via RT-PCR and adintrevimab serology EVADE Exclude: Has received a SARS-CoV-2 vaccine or convales
Slide 5: Agenda
AGENDA u CANOPY Clinical Trial Results Q&A 5
Slide 6: CANOPY: Phase 3 Clinical Trial of Pemivibart (VYD222) Study Overview
CANOPY: PHASE 3 CLINICAL TRIAL OF PEMIVIBART (VYD222) CANOPY STUDY OVERVIEW VYD222 4500 mg IV (n≈300) COHORT A Open Label Moderate-to-severe immune // compromise (N≈300) Day 1 Month 3 Month 12 (Dosing) (Redosing) (Last visit) Primary endpoints: • Safety/tolerability • Day 28 serum virus neutralizing
Slide 7: Baseline Demographics
BASELINE DEMOGRAPHICS Source: Invivyd Data on File 7
Slide 8: Medical History
MEDICAL HISTORY Cohort A Cohort B VYD222 Cohort B Placebo (N=306) (N=322) (N=162) n(%) n(%) Parameter n(%) Significant immune compromise (inclusion criteria #4a) [1] 1. actively treated solid tumor or hematologic malignancies 20 (6.5) 2. acute leukemia, chronic lymphocytic leukemia, non-Hodgkin 40 (
Slide 9: CANOPY Clinical Event 180-Day Time Period Covers a Range of COVID-19 Viruses
CANOPY CLINICAL EVENT 180-DAY TIME PERIOD COVERS A RANGE OF COVID-19 VIRUSES INCLUDING SUBSTANTIAL JN.1 IN THE SECOND HALF th Cohort B 50% Recruited: Sep 15 2023 th Cohort A 50% Recruited: Oct 15 2023 Sequence confirmation of CANOPY events underway; initial 1H analysis generally reflects U.S. CDC su
Slide 10: Safety Data Consistent with Prior Disclosures, No New Adverse Events of Special Interest
DAY 180 SAFETY DATA ARE CONSISTENT WITH PRIOR DISCLOSURES AND INCLUDE NO NEW ADVERSE EVENTS (AEs) OF SPECIAL INTEREST (ANAPHYLAXIS) COHORT A: • The most common TEAEs were viral infection (7.8%), URTI (7.5%), influenza like illness (4.2%), infusion related reactions (3.6%), and urinary tract infectio
Slide 11: Exploratory Clinical Efficacy Endpoints
EXPLORATORY CLINICAL EFFICACY ENDPOINTS Incidence of RT-PCR confirmed symptomatic COVID-19, Key Exploratory Endpoint COVID-19 related hospitalizations, and all-cause mortality as Measured through 3, 6 and 12 months Incidence of RT-PCR confirmed symptomatic COVID-19 Post-hoc COVID-19-Related Analysis
Slide 12: Cohort B: Exploratory Efficacy Endpoint
COHORT B: EXPLORATORY EFFICACY ENDPOINT Cohort B: Randomized, placebo-controlled cohort without moderate-to-severe immune compromise, at risk of acquiring SARS-CoV-2 due to regular indoor, unmasked face-to-face interactions Exploratory Efficacy Endpoint: Incidence of RT-PCR confirmed symptomatic COV
Slide 13: Clinical Protection Shown Through the Substantial JN.1 Wave in the U.S. in Early 2024
CLINICAL PROTECTION SHOWN THROUGH THE SUBSTANTIAL JN.1 WAVE IN THE U.S. IN EARLY 2024 Cohort B: Kaplan Meier on Exploratory Clinical Efficacy Endpoint 13 Source: Invivyd Data on File
Slide 14: Cohort A: Exploratory Efficacy Endpoint
COHORT A: EXPLORATORY EFFICACY ENDPOINT Cohort A: Single-arm, open-label cohort in adults with moderate-to-severe immune compromise Exploratory Efficacy Endpoint Through Day 180 Rate of symptomatic, RT-PCR confirmed COVID-19 disease 3.0% (9/298) Pemivibart (VYD222) Rate of symptomatic, RT-PCR confir
Slide 15: Clinical Protection Shown Through the Substantial JN.1 Wave in the U.S. in Early 2024
CLINICAL PROTECTION SHOWN THROUGH THE SUBSTANTIAL JN.1 WAVE IN THE U.S. IN EARLY 2024 Cohort A: Kaplan Meier on Exploratory Clinical Efficacy Endpoint 15 Source: Invivyd Data on File
Slide 16: COVID-19 Is the Most Damaging and Deadly of Prevalent Respiratory Viruses
COVID-19 IS THE MOST DAMAGING AND DEADLY OF PREVALENT RESPIRATORY VIRUSES COVID-19 is the leading cause of hospitalizations and death from respiratory viruses in the U.S. (2023-2024 data)* 1 Hospitalizations * Deaths* 2 COVID-19 460,000 45,200 3 INFLUENZA 272,000 9,900 4† RSV 179,000 ~6,000–10,000 C
Slide 17: Agenda
AGENDA u CANOPY Results u Q&A 17